Tonix Pharmaceuticals Holding Corp. · NASDAQ:TNXP
Tonix Pharmaceuticals — Investor Presentation (December 2020)
64 slides from Tonix Pharmaceuticals's investor presentation, Dec 23, 2020
Slide 1: Investor Presentation
© 2020 Tonix Pharmaceuticals Holding Corp. 1 December 2020 Version P0266 12 - 23 - 2020 (Doc 0754) Investor Presentation NASDAQ:TNXP
Slide 2: Cautionary Note on Forward-Looking Statements
© 2020 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward - Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are “forward - looking statements” as defined by the Private Securities Litigat
Slide 3: Tonix Pharmaceuticals
© 2020 Tonix Pharmaceuticals Holding Corp. 3 Tonix Pharmaceuticals © 2020 Tonix Pharmaceuticals Holding Corp . Clinical - stage biopharmaceutical company • Committed to discovering and developing innovative and proprietary new therapeutics Focus on developing biologics and small molecules • Central
Slide 4: Our Pipeline – CNS Portfolio
© 2020 Tonix Pharmaceuticals Holding Corp. 4 Our Pipeline – CNS Portfolio CANDIDATES INDICATION STATUS CNS Portfolio TNX - 102 SL 1 Fibromyalgia (FM) - Lead Program Mid - Phase 3 – ongoing PTSD Sleep Disturbance 2 Phase 3 – ready Agitation in Alzheimer’s Phase 2 ready Alcohol Use Disorder Phase 2 re
Slide 5: Our Pipeline – Immunology & Biodefense Portfolio
© 2020 Tonix Pharmaceuticals Holding Corp. 5 Our Pipeline – Immunology & Biodefense Portfolio CANDIDATES INDICATION STATUS Immunology Portfolio TNX - 1800 Covid - 19 vaccine – Prioritized Program 1 Preclinical TNX - 1810, TNX - 1820, TNX - 1830 Covid - 19 vaccine 1 Preclinical TNX - 2300 Covid - 19
Slide 6: Overview of SL
© 2020 Tonix Pharmaceuticals Holding Corp. 6 Overview of TNX - 102 SL* Protectic ® proprietary formulation of cyclobenzaprine that supports sublingual administration TNX - 102 SL is a non - opioid, centrally - acting analgesic that works by improving sleep quality Scientific Rationale for Protectic
Slide 7: SL: Differentiation from Oral Formulations
© 2020 Tonix Pharmaceuticals Holding Corp. 7 TNX - 102 SL: Differentiation from Oral Formulations FEATURE BENEFIT ADVANTAGE Cyclobenzaprine 40+ years as oral medication Established safety record Formulation: Protectic ® Allows submucosal absorption Not achievable with oral formulation Administration
Slide 8: Fibromyalgia overview and unmet need
© 2020 Tonix Pharmaceuticals Holding Corp. 8 Volkswagen Check Engine [Photograph]. (2011, October 14). Wikipedia When the check engine light malfunctions, the light is on even though the car is not malfunctioning • Fibromyalgia is considered a central nervous system disorder with symptoms that inclu
Slide 9: SL: Results from Completed FM Trials
© 2020 Tonix Pharmaceuticals Holding Corp. 9 TNX - 102 SL: Results from Completed FM Trials Completed Trials in FM: • Phase 2 (F202 BESTFIT) – 205 participants randomized • Phase 3 (F301 AFFIRM) – 519 participants randomized • Phase 3 (F304 RELIEF) – 503 participants randomized Topline Efficacy Resu
Slide 10: No Recognized Abuse Potential in Clinical Studies
© 2020 Tonix Pharmaceuticals Holding Corp. 10 No Recognized Abuse Potential in Clinical Studies Active ingredient is cyclobenzaprine, which is structurally related to tricyclic antidepressants • Cyclobenzaprine interacts with receptors that regulate sleep quality: 5 - HT 2A, a 1 - adrenergic, histam
Slide 11: Phase F304/RELIEF Study: Design
© 2020 Tonix Pharmaceuticals Holding Corp. 11 Phase 3 F304/RELIEF Study: Design Primary e ndpoint (Week 14) : • Daily diary pain severity score change (TNX - 102 SL 5.6 mg vs. placebo) from baseline in the weekly average as measured by the numerical rating scale (NRS), using mixed model repeated mea
Slide 12: F304/RELIEF Study Topline Data: Primary Endpoint Achieved
© 2020 Tonix Pharmaceuticals Holding Corp. 12 F304/RELIEF Study Topline Data: Statistical Significance Achieved on Pre - specified Primary Efficacy Endpoint (p=0.01) ◊ ◊ 2 TNX - 102 SL is in clinical stage of development and not approved for any indication Primary Outcome Measure at Week 14 Placebo
Slide 13: F304/RELIEF Study: Primary Efficacy Endpoint Results (continued)
© 2020 Tonix Pharmaceuticals Holding Corp. 13 F304/RELIEF Study: Primary Efficacy Endpoint Results (continued) -2.2 -2 -1.8 -1.6 -1.4 -1.2 -1 -0.8 -0.6 -0.4 -0.2 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 LS Mean Change from Baseline (SE) in NRS Pain Score Study Week RELIEF Study Mean Change from Baseline
Slide 14: F304/RELIEF Study: Key Secondary Efficacy Endpoints
© 2020 Tonix Pharmaceuticals Holding Corp. 14 F304/RELIEF Study: Key Secondary Efficacy Endpoints ◊ ◊ *TNX - 102 SL is in clinical stage of development and not approved for any indication Outcome Measure at Week 14 Intent - to - Treat Analysis 1 P - value Non - Specific Patient Global Impression of
Slide 15: F304/RELIEF Study: Continuous Responder Analysis Graph
© 2020 Tonix Pharmaceuticals Holding Corp. 15 P e r c e n t o f S u b j e c t s 0 10 20 30 40 50 60 70 80 90 100 Percentage Redution in Pain >=0% >=10% >=20% >=30% >=40% >=50% >=60% >=70% >=80% >=90% =100% Placebo TNX-102 SL Proportion of Subjects in Arm Cut - Off Points for Percentage Pain Responde
Slide 16: Adverse Events in F304/RELIEF Study
© 2020 Tonix Pharmaceuticals Holding Corp. 16 Adverse Events* (AEs) in F304/ RELIEF Study TNX - 102 SL (N=248) Placebo (N=255) Total (N=503) Administration Site Reactions N % N % N % Tongue/mouth numbness 43 17.3 2 0.8 45 8.9 Tongue/mouth pain/discomfort 29 11.7 5 2.0 34 6.8 Taste impairment 16 6.5
Slide 17: Safety and Tolerability in F304/RELIEF Study
© 2020 Tonix Pharmaceuticals Holding Corp. 17 Safety and Tolerability in F304/RELIEF Study • No new safety signals in RELIEF at TNX - 102 SL 5.6 mg dose • 82.3% in active arm and 83.5% in placebo arm completed the study • 8.9% in active arm and 3.9% in placebo arm discontinued due to adverse events
Slide 18: SL 5.6 mg for Fibromyalgia: Phase 3 F306/RALLY Study
© 2020 Tonix Pharmaceuticals Holding Corp. 18 TNX - 102 SL 5.6 mg for Fibromyalgia: 2 nd Phase 3 F306/RALLY Study – Enrollment Ongoing Primary e ndpoint (Week 14) : • Daily diary pain severity score change (TNX - 102 SL 5.6 mg vs. placebo) from baseline in the weekly average as measured by the numer
Slide 19: Approved Fibromyalgia Pharmacotherapies
© 2020 Tonix Pharmaceuticals Holding Corp. 19 Approved Fibromyalgia Pharmacotherapies Pfizer • Drug: Lyrica® or pregabalin (U.S. patent expired in 2018) • Approved: 2004 • Mechanism: modulates nerve impulses involved in the transmission of pain through selective binding to the alpha2 - delta protein
Slide 20: Other Fibromyalgia Pharmacotherapies in Development in the U.S.
© 2020 Tonix Pharmaceuticals Holding Corp. 20 Other Fibromyalgia Pharmacotherapies in Development in the U.S. Axsome Therapeutics - AXS - 14 • Drug: esreboxetine • Mechanism: Selective norepinephrine reuptake inhibitor • Developmental Stage: At least mid - Phase 3 (Phase 2 and Phase 3 trial positive
Slide 21: Overview of Posttraumatic Stress Disorder (PTSD)
© 2020 Tonix Pharmaceuticals Holding Corp. 21 Overview of Posttraumatic Stress Disorder (PTSD) PSTD is a chronic disabling disorder in response to experiencing traumatic event(s) Symptoms of PTSD fall into four clusters: 1. Intrusion (aversive memories, nightmares, flashbacks) 2. Avoidance (avoiding
Slide 22: PTSD: Prevalence and Demographics
© 2020 Tonix Pharmaceuticals Holding Corp. 22 PTSD: Prevalence and Demographics PTSD is a chronic response to traumatic event(s) • A majority of people will experience a traumatic event at some point in their lifetime 1 • 20% of women and 8% of men in the U.S. who experience significant trauma devel
Slide 23: SL: Hypothesized Novel Mechanism Targets Sleep Quality for PTSD
© 2020 Tonix Pharmaceuticals Holding Corp. 23 TNX - 102 SL: Hypothesized Novel Mechanism Targets Sleep Quality for Recovery from PTSD PTSD is a disorder of recovery • Most people exposed to extreme trauma recover over a few weeks • In PTSD, recovery process impeded due to insufficient sleep - depend
Slide 24: SL for PTSD: Phase P302/RECOVERY Study Design
© 2020 Tonix Pharmaceuticals Holding Corp. 24 TNX - 102 SL for PTSD: Phase 3 P302/RECOVERY, Study Design Placebo once - daily at bedtime 12 weeks TNX - 102 SL once - daily at bedtime 5.6 mg (2 x 2.8 mg tablets) General s tudy c haracteristics: • Randomized, double - blind, placebo - controlle d stud
Slide 25: P302/RECOVERY Topline Results: Efficacy Endpoints
© 2020 Tonix Pharmaceuticals Holding Corp. 25 P302/RECOVERY Topline Results Trial Efficacy Endpoints TNX - 102 SL (N=80) Placebo (N=83) TNX - 102 SL v. Placebo Week 12 Outcome Measure LS Mean SE LS Mean SE LSMD SE 95% CI p - value* ES CAPS - 5 CFB – Primary Endpoint - 20.7 1.97 - 18.5 1.9 - 2.2 2.3
Slide 26: P302/RECOVERY Topline Results: Safety Endpoints
© 2020 Tonix Pharmaceuticals Holding Corp. 26 P302/RECOVERY Topline Results Safety Endpoints TNX - 102 SL (N=80) Placebo (N=84) Change in Outcome Measure Mean 95% CI Mean 95% CI Weight (kg) 0.03 - 0.48, 0.54 0.58 - 0.01, 1.16 Systolic blood pressure (mmHg) 1.8 - 0.8, 4.5 1.3 - 1.4, 4.0 Diastolic blo
Slide 27: P302/RECOVERY Topline Results: Effects on Female Sexual Function
© 2020 Tonix Pharmaceuticals Holding Corp. 27 P302/RECOVERY Topline Results Effects of TNX - 102 SL on Female Sexual Function TNX - 102 SL (N=65) Placebo (N=64) TNX - 102 SL v. Placebo Wk 12 Outcome Measure LS Mean SE LS Mean SE LSMD SE 95% CI p - value** ES CSFQ - 14 CFB* (female) 4.6 0.84 2.4 0.86
Slide 28: SL for PTSD: Three Recent Trials
© 2020 Tonix Pharmaceuticals Holding Corp. 28 TNX - 102 SL for Posttraumatic Stress Disorder (PTSD): Three Recent Trials Phase 3 P302 “RECOVERY” – Civilian PTSD (79% female) 1 • Reported Topline in December 2020 ( mITT , N = 163) • 2 groups: Placebo (n = 83) and TNX 5.6 mg (n = 80) • Primary endpoin
Slide 29: Adverse Event Profile of SL 5.6 mg in PTSD Trials
© 2020 Tonix Pharmaceuticals Holding Corp. 29 Adverse Event Profile of TNX - 102 SL 5.6 mg in Phase 3 Trials in Both Civilian (P302) and Military - Related (P301) PTSD # Only adverse events (AEs) are listed that are at a rate of ≥ 5% in the TNX - 102 SL - treated groups *No values in a row for eithe
Slide 30: Common Observations from Three Recent PTSD Trials
© 2020 Tonix Pharmaceuticals Holding Corp. 30 Common Observations from Three Recent PTSD Trials Testing TNX - 102 SL • Consistent nominal improvement or trend at Week 12 for sleep measurements • Supported by nominal benefits in PROMIS Sleep Disturbance and E6 sleep disturbance item in CAPS - 5 analy
Slide 31: Sleep Disturbance Recognized as Clinically Valid Approach to Address PTSD
© 2020 Tonix Pharmaceuticals Holding Corp. 31 Sleep Disturbance Recognized as Clinically Valid Approach to Address PTSD VA Study on Sleep in PTSD currently recruiting: non - registrational 4 - arm study of trazodone, eszopiclone, gabapentin and placebo on VA PTSD patients 1 • Insomnia Severity Index
Slide 32: Future Plans: SL for PTSD
© 2020 Tonix Pharmaceuticals Holding Corp. 32 Future Plans: TNX - 102 SL for PTSD Plan to propose new indication: “treatment of sleep disturbance associated with PTSD” • Sleep disturbance is a core symptom of PTSD • TNX - 102 SL works by improving sleep quality which, as a result, improves sleep - d
Slide 33: SL Intellectual Property – U.S. Protection expected until 2035
© 2020 Tonix Pharmaceuticals Holding Corp. 33 TNX - 102 SL Intellectual Property – U.S. Protection expected until 2035 • United States Patent and Trademark Office (USPTO) issued United States Patent No. 9636408 in May 2017, Patent No. 9956188 in May 2018, Patent No. 10117936 in November 2018, Patent
Slide 34: Opportunities to Expand SL to Other Indications
© 2020 Tonix Pharmaceuticals Holding Corp. 34 Opportunities to Expand TNX - 102 SL to Other Indications Growing recognition that there are many disorders where sleep disturbances may have a role in the pathophysiology (cardiovascular, metabolic, neurologic) • Sleep quality plays a homeostatic role i
Slide 35: TNX-1800: a COVID-19 Vaccine Candidate
© 2020 Tonix Pharmaceuticals Holding Corp. 35 TNX - 1800 1 : a COVID - 19 Vaccine Candidate • Utilizes Tonix’s proprietary horsepox virus as a vector • Encodes a protein from SARS - CoV - 2, the cause of COVID - 19 • Developed in collaboration with University of Alberta, Canada • Animal testing with
Slide 36: COVID-19 Vaccine Landscape
© 2020 Tonix Pharmaceuticals Holding Corp. 36 COVID - 19 Vaccine Landscape • We expect more than one vaccine will be approved by FDA • Different vaccines for different individuals • More than 150 vaccines in development • Diversity of approaches is important since protective immunity is not yet unde
Slide 37: Live, Attenuated Virus Vaccines for Other Infectious Diseases
© 2020 Tonix Pharmaceuticals Holding Corp. 37 Live, Attenuated Virus Vaccines for Other Infectious Diseases 1 • Long term, durable immunity • Expected to stimulate T cells and provide years to decades of protection • Single administration, scalable manufacturing • Low dose is amplified by replicatio
Slide 38: TNX-1800 Vaccination of Non-Human Primates Elicited Neutralizing Antibodies
© 2020 Tonix Pharmaceuticals Holding Corp. 38 TNX - 1800 Vaccination of Non - Human Primates Elicited Anti - SARS - CoV - 2 Neutralizing Antibodies and Skin Reaction or “Take” in All Eight Animals STUDY DESIGN : Compares TNX - 1800 (modified horsepox virus encoding CoV - 2 spike protein) to TNX -
Slide 39: TNX-1800 Vaccination of Non-Human Primates: Findings, Conclusions and Next Phase
© 2020 Tonix Pharmaceuticals Holding Corp. 39 TNX - 1800 Vaccination of Non - Human Primates Findings, Conclusions and Next Phase TOLERABILITY : TNX - 1800 and TNX - 801 were well tolerated at both doses. DOSE: Supports the expectation that TNX - 1800 at the low dose of 1 x 10 6 PFU is an approp
Slide 40: TNX-1800: Engineered for Long-term Immunity
© 2020 Tonix Pharmaceuticals Holding Corp. 40 TNX - 1800 1 : Engineered for Long - term Immunity • Based on “vaccinia” vaccine developed more than 200 years ago by Dr. Edward Jenner to prevent smallpox • TNX - 1800 has 99.7% colinear identity with circa 1860 smallpox vaccine 2 • Eradicated smallpox
Slide 41: Why Use a Horsepox Platform for a Vaccine?
© 2020 Tonix Pharmaceuticals Holding Corp. 41 Why Use a Horsepox Platform for a Vaccine? Horsepox can be engineered to express foreign genes • Lack of persistence or genomic integration in the host • Strong immunogenicity as a vaccine • Readily manufacture at scale • Live, attenuated vaccine – direc
Slide 42: TNX-1800 is Based on a Horsepox Virus Vector
© 2020 Tonix Pharmaceuticals Holding Corp. 42 TNX - 1800 is Based on a Horsepox Virus (HPXV) Vector Designed to Express SARS - CoV - 2 S Protein *TNX - 1800 is at the pre - IND stage of development Horsepox sHPXV ~200,000 Bp TNX - 1800 * rHPXV/SARS - CoV - 2S ~200,000 Bp Homologous Recombination
Slide 43: Vaccinia Induces a Skin Reaction Called “Take”
© 2020 Tonix Pharmaceuticals Holding Corp. 43 Vaccinia Induces a Skin Reaction Called “Take” – Described by Dr. Edward Jenner 1. Fulginiti VA, et al. Clin Infect Dis. 2003;37(2):241 - 250. 2. Liu L, et al. Nature Med. 2010;16(2):224 - 228. 3. Centers for Disease Control and Prevention. Accessed Apri
Slide 44: Unique Challenges of SARS-CoV-2
© 2020 Tonix Pharmaceuticals Holding Corp. 44 Unique Challenges of SARS - CoV - 2 SARS Rate of death 1,2 Deaths 2 Rate of infectivity 1 Incubation time 2 Asymptomatic 3 0.4 2 - 7 days ~13% ~10% SARS - CoV - 2 Rate of death 1,4 Deaths (as of Nov. 2020) 5 Rate of infectivity 1,4 Incubation time 2,4 As
Slide 45: Infection of Type II Pneumocytes Can Lead to Lethal Respiratory Illness
© 2020 Tonix Pharmaceuticals Holding Corp. 45 Infection of Type II Pneumocytes Can Lead to Lethal Respiratory Illness Capillary Type II pneumocytes Inhalation Exhalation Type II pneumocytes in the alveoli secrete pulmonary surfactants that are necessary for effective gas exchange. 2 SARS - CoV - 2 I
Slide 46: SARS-CoV-2 Hijacks the Respiratory System to Spread Virus
© 2020 Tonix Pharmaceuticals Holding Corp. 46 SARS - CoV - 2 Hijacks the Respiratory System to Spread Contagious Virus Respiratory epithelium Capillary Airway Resting CD8 T cell Endothelial cell Exhalation spreads virus • Virus factories release virions by continuous budding • Breathing, speaking or
Slide 47: CoV-Specific T Cells Kill the Virus Factories
© 2020 Tonix Pharmaceuticals Holding Corp. 47 CoV - 2 Specific T Cells Kill the Virus Factories • Natural immunity or vaccine protection has the potential to decrease forward transmission • T cells specifically kill virally infected cells Bar - On YM, et al. eLife . 2020;9:e57309 . Respiratory epith
Slide 48: Contrasting T cell and Antibody Immunity
© 2020 Tonix Pharmaceuticals Holding Corp. 48 Contrasting T cell and Antibody Immunity • T cell immunity • Durable or long - lived (many years) • Recognize fragments of pathogens on the surfaces of infected cells • Cannot recognize pathogens directly • Potential to clear viral infections (by killing
Slide 49: TNX-1800 Upcoming Milestones
© 2020 Tonix Pharmaceuticals Holding Corp. 49 TNX - 1800 Upcoming Milestones Southern Research studies will address two key questions: • Will vaccination of animals elicit an immune response to the S protein? • 4 th Quarter 2020 - Non - human primate immune response positive results reported • Will
Slide 50: SARS-CoV-2 Vaccine Platform: Bovine Parainfluenza Virus
© 2020 Tonix Pharmaceuticals Holding Corp. 50 2 nd SARS - CoV - 2 Vaccine Platform: Bovine Parainfluenza (BPI) Virus Collaboration with Kansas State University to develop a vaccine candidate for the prevention of COVID - 19 • Utilizes a novel live attenuated vaccine vector platform and the CD40 - li
Slide 51: TNX-1300 for the Treatment of Cocaine Intoxication
© 2020 Tonix Pharmaceuticals Holding Corp. 51 TNX - 1300* for the Treatment of Cocaine Intoxication Recombinant protein that degrades cocaine in the bloodstream 1 • Double - mutant cocaine esterase ( CocE ) • CocE was identified in a bacterium ( Rhodococcus ) that use cocaine as its sole source of c
Slide 52: TNX-1300 Is a Fast-acting Cocaine Antidote
© 2020 Tonix Pharmaceuticals Holding Corp. 52 TNX - 1300 (Cocaine Esterase or CocE ) Is a Fast - acting Cocaine Antidote CocE Rhodococcus bacteria living in the roots of the coca plant use CocE to metabolize cocaine 1 CocE cleaves chemical bonds in cocaine and disintegrates it 800 times faster than
Slide 53: TNX-1300 Development Plan
© 2020 Tonix Pharmaceuticals Holding Corp. 53 TNX - 1300 Development Plan 53 • Targeting to initiate a Phase 2 open - label, randomized pilot study of TNX - 1300 in the first quarter of 2021 • Emergency department (ED) setting with patients coming in for treatment of cocaine and/or polysubstance int
Slide 54: TNX-1900 for Migraine and Craniofacial Pain – Overview
© 2020 Tonix Pharmaceuticals Holding Corp. 54 TNX - 1900 for the Treatment of Migraine and Craniofacial Pain – Overview Novel intranasal oxytocin formulation being developed as a prophylactic treatment for chronic migraine • Based on a propriety formulation of oxytocin*, a naturally occurring human
Slide 55: TNX-1900 for the Treatment of Migraine – Prevalence
© 2020 Tonix Pharmaceuticals Holding Corp. 55 TNX - 1900 for the Treatment of Migraine – Prevalence One billion individuals worldwide suffer from migraines (~14% of population) 1 Migraine is the second leading cause of years lived with disability 1 In U.S., the estimated cost of all migraine headach
Slide 56: TNX-1900 for Migraine – Mechanism of Action
© 2020 Tonix Pharmaceuticals Holding Corp. 56 TNX - 1900 for the Treatment of Migraine – Mechanism of Action Preclinical research showed that nasally applied TNX - 1900 selectively inhibits the activity of trigeminal pain - sensing nerve cells and blocks the release of CGRP • TNX - 1900 is believed
Slide 57: TNX-1900 for Migraine – Mechanism of Action (continued)
TNX - 1900 for the Treatment of Migraine – Mechanism of Action (continued) HEAD PAIN PATIENT USES TNX - 1900 TARGETED DELIVERY Permeates nasal mucosa Transported to trigeminal system and brain Proprietary Nasal to Brain Delivery CGRP: NEUROTRANSMITTER THAT HAS BEEN VALIDATED AS KEY MIGRAINE TARGET T
Slide 58: TNX-1900: Mechanism of Action (continued)
TNX - 1900: Mechanism of Action (continued) In animal models, intranasal oxytocin concentrates in the trigeminal system I nhibits trigeminal neuronal firing, and decreases CGRP (and PACP) release onto meningeal vasculature and within the brainstem - Believed to have effects on: - Neurogenic inflamma
Slide 59: TNX-1900 for Migraine – Development Status
© 2020 Tonix Pharmaceuticals Holding Corp. 59 TNX - 1900 for the Treatment of Migraine – Development Status In June 2020, Tonix acquired a proprietary formulation of nasal oxytocin solution for intranasal delivery from Trigemina Also acquired migraine and pain treatment technologies of Trigemina , I
Slide 60: Pipeline Summary – by Select Therapeutic Areas
© 2020 Tonix Pharmaceuticals Holding Corp. 60 Pipeline 1 Summary – by Select Therapeutic Areas Pain Psychiatry Addiction Medicine • TNX - 102 SL (sublingual cyclobenzaprine) for fibromyalgia Phase 3/RELIEF Phase 3/RALLY • TNX - 102 SL (sublingual cyclobenzaprine) for PTSD Sleep Disturbance Phase 3/R
Slide 61: Pipeline Summary – by Select Therapeutic Areas (continued)
© 2020 Tonix Pharmaceuticals Holding Corp. 61 Pipeline 1 Summary – by Select Therapeutic Areas (continued) Oncology • TNX - 1700 (rTFF2 2 ) for treatment of gastric and pancreatic cancer Preclinical Public Health • TNX - 1800, TNX - 1810, TNX - 1820 & TNX - 1830 (live modified horsepox vaccine) for
Slide 62: Milestones – Recently Completed and Upcoming
© 2020 Tonix Pharmaceuticals Holding Corp. 62 Milestones – Recently Completed and Upcoming 1 □ September 2020 Interim analysis of TNX - 102 SL Phase 3 F304/RELIEF study in fibromyalgia completed □ 4 th Quarter 2020 Non - human primate immune response positive results reported □ 4 th Quarter 2020 Pos
Slide 63: Management Team
© 2020 Tonix Pharmaceuticals Holding Corp. 63 Management Team Seth Lederman, MD President & CEO Jessica Morris Chief Operating Officer Gregory Sullivan, MD Chief Medical Officer Bradley Saenger , CPA Chief Financial Officer
Slide 64: Thank You!
© 2020 Tonix Pharmaceuticals Holding Corp. 64 Thank You!
Tonix Pharmaceuticals Holding — Investor Presentation (December 2020) on 6ix